Comparative risk of uveitis with Janus kinase inhibitors versus tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic diseases: a target trial emulation study

In this large-scale, real-world cohort study, JAKi therapy was associated with a significantly reduced risk of incident uveitis compared to TNFi therapy in patients with AS, PsO, or PsA. These findings suggest a potential role for JAKi in mitigating ocular inflammation in this population. Further prospective studies and randomized controlled trials are warranted to validate these results and inform future clinical guidelines.